GLP-1 Research Study
Researchers at the Johns Hopkins School of Medicine are conducting a research study on how GLP-1 medications influence appetite in adults.
Fast Facts
Currently taking Wegovy or Zepbound
18+
Years Old
Compensation
Provided Up To $50
Conducted in
Baltimore, Maryland
Study Background
GLP-1 medications may change not only how much people eat, but also food-related decision-making.
GLP-1 medications such as Wegovy and Zepbound are widely used for weight management, yet relatively little is known about how these medications affect food choice and responses to food-related cues. Understanding these effects may help researchers better explain changes in eating behavior that occur while taking these medications.
This study specifically seeks individuals currently taking Wegovy or Zepbound. Individuals taking other GLP-1 medications (e.g., Trulicity, Victoza, Byetta) are not eligible.
This study aims to examine how individuals taking GLP-1 medications respond to different food cues. The findings may contribute to a better understanding of how weight loss pharmacotherapies influence eating patterns.
Study Background
GLP-1 medications may change not only how much people eat, but also food-related decision-making.
GLP-1 medications may change not only how much people eat, but also food-related decision-making.
GLP-1 medications such as Wegovy and Zepbound are widely used for weight management, yet relatively little is known about how these medications affect food choice and responses to food-related cues. Understanding these effects may help researchers better explain changes in eating behavior that occur while taking these medications.
This study specifically seeks individuals currently taking Wegovy or Zepbound. Individuals taking other GLP-1 medications (e.g., Trulicity, Victoza, Byetta) are not eligible.
This study aims to examine how individuals taking GLP-1 medications respond to different food cues. The findings may contribute to a better understanding of how weight loss pharmacotherapies influence eating patterns.
Additional Information
This study is being conducted to better understand how GLP-1 medications influence taste, smell, and eating behaviors in adults using these treatments for weight management.
You may be eligible for this study if you meet the following criteria.
Inclusion Criteria:
- Adults 18 years or older
- Currently using a GLP-1 receptor agonist (Wegovy or Zepbound) for ≥ 3 months
- Fluent in English
Exclusion Criteria:
- History or current diagnosis of an eating disorder
- Current diagnosis of depressive disorders or other significant psychiatric conditions
- Current use of antidepressant medications
- Diagnosis of diabetes
- Current pregnancy or lactation
- Tobacco use/vaping
If you choose to participate, you will first complete a 5-10 minute confidential screening call to determine eligibility. If eligible, you will attend one in-person visit at the Johns Hopkins East Baltimore campus that lasts approximately 2–3 hours. During the visit, you will complete questionnaires about your eating behaviors and food preferences and take part in food selection tasks.
Yes. Participants will receive $50 for completing the in-person study visit. Parking validation will be provided at the study location.
There is no cost for you to participate in our research study.
IRB00462589 Principal Investigator: Kimberly Smith, PhD